Abstract
Introduction: With increasing life expectancy, curative treatment of octogenarians with urothelial carcinoma of the bladder (UCB) becomes more important. Materials and Methods: The treatment modalities of 276 octogenarians with UCB who were treated at the University Hospital of Erlangen between 1982 and 2011 were assessed retrospectively. Results: One hundred forty-six patients had non-muscle invasive bladder cancer (NMIBC) while 71 had muscle invasive bladder cancer (MIBC). No data was available for 59 patients. Eighty-five (58.2%) of the 146 patients with NMIBC received transurethral resection of the bladder tumor (TURBT) only, another 38 patients (26%) underwent additional intravesical therapy; and 8.9% were treated with radiochemotherapy (RCT), 4.1% with radiotherapy (RT), 1.4% with systemic chemotherapy and 1.4% with radical cystectomy (RC). Of the 71 patients suffering from MIBC, 39 (54.9%) received TURBT alone. A potentially curative therapy was performed on 31 of the 71 patients with MIBC (43.7%). Of these, 16 patients (51.6%) received RCT, 9 patients (29.0%) RT and 6 patients (19.4%) RC. In Kaplan-Meier analysis, patients with MIBC had better median overall survival with curative treatment compared to TURBT alone (28 vs. 9 months; p < 0.001, log-rank test). Conclusions: By offering a wide range of treatment options, over 43% of octogenarians with MIBC received a curative therapy at a maximum care hospital.
References
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.
2.
Prout GR Jr, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK: Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer 2005;104:1638-1647.
3.
Schultzel M, Saltzstein SL, Downs TM, Shimasaki S, Sanders C, Sadler GR: Late age (85 years or older) peak incidence of bladder cancer. J Urol 2008;179:1302-1305; discussion 1305-1306.
4.
Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y: Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234-241.
5.
Hautmann RE, Abol-Enein H, Davidsson T, Gudjonsson S, Hautmann SH, Holm HV, Lee CT, Liedberg F, Madersbacher S, Manoharan M, Mansson W, Mills RD, Penson DF, Skinner EC, Stein R, Studer UE, Thueroff JW, Turner WH, Volkmer BG, Xu A; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012: ICUD-EAU international consultation on bladder cancer 2012: urinary diversion. Eur Urol 2013;63:67-80.
6.
Hollenbeck BK, Miller DC, Taub D, Dunn RL, Underwood W 3rd, Montie JE, Wei JT: Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology 2004;64:292-297.
7.
Donat SM, Siegrist T, Cronin A, Savage C, Milowsky MI, Herr HW: Radical cystectomy in octogenarians - does morbidity outweigh the potential survival benefits? J Urol 2010;183:2171-2177.
8.
Garde H, Ciappara M, Galante I, Fuentes Ferrer M, Gómez A, Blazquez J, Moreno J: Radical cystectomy in octogenarian patients: a difficult decision to take. Urol Int 2015;94:390-393.
9.
Comploj E, West J, Mian M, Kluth LA, Karl A, Dechet C, Shariat SF, Stief CG, Trenti E, Palermo S, Lodde M, Horninger W, Madersbacher S, Pycha A: Comparison of complications from radical cystectomy between old-old versus oldest-old patients. Urol Int 2015;94:25-30.
10.
Shariat SF, Milowsky M, Droller MJ: Bladder cancer in the elderly. Urol Oncol 2009;27:653-667.
11.
Konety BR, Joslyn SA: Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. J Urol 2003;170:1765-1771.
12.
Snyder C, Harlan L, Knopf K, Potosky A, Kaplan R: Patterns of care for the treatment of bladder cancer. J Urol 2003;169:1697-1701.
13.
Taylor JA 3rd, Kuchel GA: Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract Urol 2009;6:135-144.
14.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
15.
Manton KG, Vaupel JW: Survival after the age of 80 in the United States, Sweden, France, England, and Japan. N Engl J Med 1995;333:1232-1235.
16.
Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R: Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20:3061-3071.
17.
Ott OJ, Rödel C, Weiss C, Wittlinger M, St Krause F, Dunst J, Fietkau R, Sauer R: Radiochemotherapy for bladder cancer. Clin Oncol (R Coll Radiol) 2009;21:557-565.
18.
Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R, Rödel C: Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007;68:1072-1080.
19.
Goossens-Laan CA, Visser O, Hulshof MC, Wouters MW, Bosch JL, Coebergh JW, Kil PJ: Survival after treatment for carcinoma invading bladder muscle: a Dutch population-based study on the impact of hospital volume. BJU Int 2012;110:226-232.
20.
Mayr R, May M, Burger M, Martini T, Pycha A, Dechet C, Lodde M, Comploj E, Wieland WF, Denzinger S, Otto W, Aziz A, Fritsche HM, Gierth M: The Charlson comorbidity index predicts survival after disease recurrence in patients following radical cystectomy for urothelial carcinoma of the bladder. Urol Int 2014;93:303-310.
21.
Berger I, Wehrberger C, Ponholzer A, Wolfgang M, Martini T, Breinl E, Dunzinger M, Hofbauer J, Höltl W, Jeschke K, Krause SF, Kugler W, Rauchenwald M, Pauer W, Pycha A, Madersbacher S: Impact of the use of bowel for urinary diversion on perioperative complications and 90-day mortality in patients aged 75 years or older. Urol Int 2015;94:394-400.
22.
Harraz AM, Osman Y, El-Halwagy S, Laymon M, Mosbah A, Abol-Enein H, Shaaban AA: Risk factors of hospital readmission after radical cystectomy and urinary diversion: analysis of a large contemporary series. BJU Int 2015;115:94-100.
23.
Novotny V, Zastrow S, Koch R, Wirth MP: Radical cystectomy in patients over 70 years of age: impact of comorbidity on perioperative morbidity and mortality. World J Urol 2012;30:769-776.
24.
Morgan TM, Barocas DA, Keegan KA, Cookson MS, Chang SS, Ni S, Clark PE, Smith JA Jr, Penson DF: Volume outcomes of cystectomy - is it the surgeon or the setting? J Urol 2012;188:2139-2144.
25.
Eastham JA: Do high-volume hospitals and surgeons provide better care in urologic oncology? Urol Oncol 2009;27:417-421.
26.
Solsona E, Iborra I, Collado A, Rubio-Briones J, Casanova J, Calatrava A: Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol 2010;184:475-480.
27.
Herr HW: Age and outcome of superficial bladder cancer treated with bacille Calmette-Guérin therapy. Urology 2007;70:65-68.
28.
Heiner JG, Terris MK: Effect of advanced age on the development of complications from intravesical bacillus Calmette-Guérin therapy. Urol Oncol 2008;26:137-140.
29.
Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG, Sherif A; European Association of Urology: EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014;65:778-792.
30.
Krause FS, Walter B, Ott OJ, Häberle L, Weiss C, Rödel C, Wullich B, Sauer R: 15-Year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res 2011;31:985-990.
31.
Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, Zietman AL: Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705-711.
32.
Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W: Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol 2014;66:120-137.
33.
Weiss C, Wolze C, Engehausen DG, Ott OJ, Krause FS, Schrott KM, Dunst J, Sauer R, Rödel C: Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol 2006;24:2318-2324.
34.
Gore JL, Litwin MS, Lai J, Yano EM, Madison R, Setodji C, Adams JL, Saigal CS; Urologic Diseases in America Project: Use of radical cystectomy for patients with invasive bladder cancer. J Natl Cancer Inst 2010;102:802-811.
35.
Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Lin CC, Zietman AL, Virgo KS: Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the national cancer data base. Eur Urol 2013;63:823-829.
36.
James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, Crundwell M, Sizer B, Sreenivasan T, Hendron C, Lewis R, Waters R, Huddart RA; Investigators BC2001: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366:1477-1488.
37.
Wittlinger M, Rödel CM, Weiss C, Krause SF, Kühn R, Fietkau R, Sauer R, Ott OJ: Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol 2009;93:358-363.
38.
Tung MC, Hsieh MJ, Wang SS, Yang SF, Chen SS, Wang SW, Lee LM, Lee WJ, Chien MH: Associations of VEGF-C genetic polymorphisms with urothelial cell carcinoma susceptibility differ between smokers and non-smokers in Taiwan. PLoS One 2014;9:e91147.
39.
Keck B, Wach S, Taubert H, Zeiler S, Ott OJ, Kunath F, Hartmann A, Bertz S, Weiss C, Hönscheid P, Schellenburg S, Rödel C, Baretton GB, Sauer R, Fietkau R, Wullich B, Krause FS, Datta K, Muders MH: Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients. Int J Cancer 2015;136:443-451.
40.
Li S, Wu J, Chen Y, Tang W, Peng Q, Deng Y, Xie L, Wang J, Huang S, Li R, Qin X, Zhao J: ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis. Anticancer Drugs 2014;25:106-114.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
